XM does not provide services to residents of the United States of America.
D
D

DaVita


News

DaVita Appoints David Maughan As Chief Operating Officer

BRIEF-DaVita Appoints David Maughan As Chief Operating Officer Sept 13 (Reuters) - DaVita Inc DVA.N : DAVITA APPOINTS DAVID MAUGHAN NEW CHIEF OPERATING OFFICER, MIKE STAFFIERI STEPS INTO EMERITUS ROLE Source text for Eikon: ID:nPn89slw5a Further company coverage: DVA.N
D

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change Warner Bros Discovery Inc WBD.OQ +7.6% Kroger Co KR.N +5.6% Axon Enterprise Inc AXON.OQ +4.3% DaVita Inc DVA.N +4.0% Dollar General Corp DG.N +3.9% Bottom Performers Percent Change Moderna Inc MRNA.OQ -17.1% Micron Technology Inc MU.OQ
K
M
T
O
U
E
D

U.S. Cintas, Sprouts Farmers Market, Voya Financial

U.S. RESEARCH ROUNDUP-Cintas, Sprouts Farmers Market, Voya Financial Sept 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cintas Corp, Sprouts Farmers market and Voya Financial, on Thursday. HIGHLIGHTS * Ally Financial Inc ALLY.N : RBC cuts target price to $40 from $49 * Cintas Corp CTAS.O : CFRA adjusts target price to $170 from $645 to reflect 4-for-1 stock split * Gilead GILD.O : Raymond James raises target pri
C
E
G
L
N
P
S
E
A
D
E
L

U.S. STOCKS Primerica, Affirm Holdings, 3D Systems

BUZZ-U.S. STOCKS ON THE MOVE-Primerica, Affirm Holdings, 3D Systems Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 inched up in choppy trading on Friday ahead of a long weekend, after signs of moderating price pressures, strengthened bets for an interest-rate cut at the U.S.
A
G
I
N
U
U
U
D
D

Nuwellis and Davita Mutually Agree To Terminate Supply And Collaboration Agreement

BRIEF-Nuwellis and Davita Mutually Agree To Terminate Supply And Collaboration Agreement Aug 22 (Reuters) - DaVita Inc DVA.N : NUWELLIS - CO, DAVITA INC MUTUALLY AGREED TO TERMINATE ITS SUPPLY AND COLLABORATION AGREEMENT, DATED AS OF JUNE 19, 2023 Source text for Eikon: [ID:n0001140361-24-038108] Further company coverage: DVA.N
D

U.S. Alight, Mastercard, Visa

U.S. RESEARCH ROUNDUP-Alight, Mastercard, Visa Aug 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alight, Mastercard and Visa, on Tuesday. HIGHLIGHTS * Alight Inc ALIT.N : JP Morgan cuts to neutral from overweight * Biomarin Pharmaceutical Inc BMRN.O : Bernstein raises to outperform from market-perform * Liquidia Corp LQDA.O : Raymond James raises to strong buy from outperform * Mastercard MA.N : JP Morgan raises
A
A
B
D
P
P
V
A
D
T
A
E
F
G
Z
B
D

DaVita Inc reports results for the quarter ended in June - Earnings Summary

DaVita Inc reports results for the quarter ended in June - Earnings Summary DaVita Inc DVA.N reported quarterly adjusted earnings of $2.50​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.91. The mean expectation of six analysts for the quarter was for earnings of $2.54 per share.
D

DaVita lifts annual profit forecast on strong kidney dialysis services demand

DaVita lifts annual profit forecast on strong kidney dialysis services demand Aug 6 (Reuters) - Healthcare company DaVita DVA.N raised its 2024 profit forecast on Tuesday expecting strong demand for its kidney dialysis services, sending shares of the company up 3% in aftermarket trade. Shares of DaVita, similar to those of its peers, witnessed a steep fall in October last year and gradually recovered in 2024, after the company downplayed speculations over the impact of new GLP-1 weight-loss drug
D

DaVita Q2 EPS USD 2.5

BRIEF-DaVita Q2 EPS USD 2.5 Aug 06 (Reuters) - DaVita Q2 operating income USD 506 million. Q2 operating cash flow USD 799 million Q2 free cash flow USD 654 million Q2 adjusted EPS USD 2.59 vs. IBES estimate USD 2.54
D

Rollercoaster markets, Nikkei rebounds 10%

MORNING BID AMERICAS-Rollercoaster markets, Nikkei rebounds 10% A look at the day ahead in U.S. and global markets from Mike Dolan The speed and scale of Tuesday's 10% Tokyo bounce after its worst day in 37 years suggests the wild global market swings of the past week are more rooted in speculative churn than economic fright. While that's only partly reassuring - as persistent market turbulence can itself sap economic activity - there's good reason to believe a slowing U.S.
A
C
N
U
W
J
U
U
U
F
F
D
I
J
M
S
B

DaVita Inc <DVA.N> expected to post earnings of $2.54 a share - Earnings Preview

DaVita Inc expected to post earnings of $2.54 a share - Earnings Preview DaVita Inc DVA.N , DVA is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2024 The Denver Colorado-based company is expected to report a 5.1% increase in revenue to $3.152 billion from $3 billion a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
D

DaVita falls on reaching agreement with US DOJ to resolve illegal kickback allegations

BUZZ-DaVita falls on reaching agreement with US DOJ to resolve illegal kickback allegations ** Shares of healthcare company DaVita DVA.N fall 2.8% to $135.93 in afternoon trade ** Co mpany says it has agreed to pay over $34 mln to the U.S. Department of Justice (DOJ) for resolving allegations of paying illegal kickbacks to nephrologists and vascular access physicians to induce referral of patients to its dialysis centers ** DOJ alleges DaVita paid "improper remuneration" to a large nephrology pr
F
D

U.S. Justice Department Says Davita To Pay Over $34 Million To Resolve Allegations Of Illegal Kickbacks

BRIEF-U.S. Justice Department Says Davita To Pay Over $34 Million To Resolve Allegations Of Illegal Kickbacks July 18 (Reuters) - DaVita Inc DVA.N : U.S. JUSTICE DEPARTMENT SAYS DAVITA TO PAY OVER $34 MILLION TO RESOLVE ALLEGATIONS OF ILLEGAL KICKBACKS Source text for Eikon: [ID:] Further company coverage: DVA.N (Reporting By Eric Beech)
D

U.S. STOCKS Morgan Stanley, Datadog, Berkshire Hathaway

BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Datadog, Berkshire Hathaway Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street jumped in upbeat trading on Monday, on a greater chance of presidential candidate Donald Trump winning a second term after surviving an assassination attempt, while interest-rate cut hopes also aided market sentiment.
A
A
C
G
T
U
U
D

DaVita falls on report of FTC launching an investigation into co

BUZZ-DaVita falls on report of FTC launching an investigation into co ** Shares of dialysis firm DaVita DVA.N fall 2.8% to $137.59 ** The U.S. Federal Trade Commission is investigating DVA and Fresenius Medical Carev FMEG.DE over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday ** The F
F
D

US FTC probing DaVita, Fresenius Medical, Politico reports

UPDATE 1-US FTC probing DaVita, Fresenius Medical, Politico reports Adds more details in paragraph 4, background in paragraph 6 July 13 (Reuters) - The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita DVA.N and Fresenius Medical Care FMEG.DE over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.
F
D

US Federal Trade Commission Is Investigating Dialysis Providers Davita And Fresenius Medical Care- Politico

BRIEF-US Federal Trade Commission Is Investigating Dialysis Providers Davita And Fresenius Medical Care- Politico July 13 (Reuters) - US FEDERAL TRADE COMMISSION IS INVESTIGATING DIALYSIS PROVIDERS DAVITA AND FRESENIUS MEDICAL CARE- POLITICO Source https://tinyurl.com/ym3t3yby
F
D

US FTC probing DaVita, Fresenius Medical, Politico reports

US FTC probing DaVita, Fresenius Medical, Politico reports July 13 (Reuters) - The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita DVA.N and Fresenius Medical Care FMEG.DE over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.
F
D



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.